CAPRA-EVO: a Randomized Serial PCCT Trial of Early Evolocumab After ACS | MicrobiomeTrials← Back to trialsNCT07612774
CAPRA-EVO: a Randomized Serial PCCT Trial of Early Evolocumab After ACS
RecruitingPHASE4INTERVENTIONAL
Trial Details
Start: 2026-05-19Est. Completion: 2028-12-31
Enrollment target: 233 participants Locations- West China Hospital of Sichuan University, Chengdu, Sichuan, China
Other microbiome trials you might be interested in
Insulin ResistanceObesity
Background:
Obesity and related illnesses cause at least 2.8 million deaths each year worldwide. Few treatments exist f…
Bethesda, United StatesEst. completion Mar 1, 2030
Chronic Venous Insufficiency, CVI
This is a prospective, single-arm, pre-post interventional study designed to evaluate the feasibility, safety, and impac…
Bydgoszcz, PolandCompleted May 10, 2028
Recruiting
Cardiovascular DiseasesLifestyle Factors
Unhealthy lifestyle behaviors are well-established risk factors for cardiovascular disease (CVD) which is the leading ca…
Gävle, SwedenEst. completion Dec 2027